Experienced CMO on board

In mid-November, Marseille-based DiogenX announced the appointment of Dr Klara Owen as Chief Medical Officer. The French biotech start-up, which was founded in 2020, focuses on the regeneration of insulin-producing beta cells for the treatment of diabetes. With the appointment of Owen, the management team now appears to be complete. The last strengthening of the team took place in this summer.

Owen brings to DiogenX many years of experience in the field of diabetes and metabolic disorders from both a clinical and entrepreneurial perspective. In particular, she has spent the last ten years in senior positions in leading international pharmaceutical and biotech companies

She joins DiogenX from Novo Nordisk, where she was Senior International Medical Director of Cell Therapy R&D. Prior to that, she was Medical Director at Zealand Pharma for almost four years. Prior to that, she was also at Novo Nordisk, where she spent five years as International Medical Director in various indications for insulins and incretins, from FHD to Phase 3b.

Klara Owen received her medical degree and PhD from Charles University in Prague (Czech Republic). At the beginning of her career, she spent over a decade in clinical practice and education. During her seven years of teaching at the 1st Faculty of Medicine at Charles Universitx, she also obtained a specialist qualification in diabetology. Owen furthered her education with an MSc in Drug Development Science at King’s College London (UK).